AG真人官方

Intensity Therapeutics (INTS) is soliciting stockholder approval for an amendment to implement a Reverse Stock Split and an adjournment proposal. As of the Record Date there were 49,055,462 shares outstanding; a quorum requires holders of at least 16,351,821 shares. The proposed Reverse Stock Split would proportionally reduce outstanding shares to between 9,811,092 and 1,635,182 shares depending on the split ratio chosen, and would increase the number of authorized but unissued shares. The board unanimously recommends a vote FOR the Amendment Proposal.

The proxy explains effects on fractional shares (cash paid in lieu), adjustments to options/warrants, no change to par value ($0.0001), and potential dilution from future issuances. The company notes capital needs and intends to seek additional financing, including an At-The-Market agreement with H.C. Wainwright. The filing summarizes U.S. federal income tax consequences, including that cash for fractions may generate capital gain or backup withholding.

Intensity Therapeutics (INTS) is asking shareholders to approve an amendment to implement a reverse stock split within a split ratio range set by the board, intended to reduce outstanding shares and potentially raise the per-share market price. The statement notes the closing price on August 27, 2025 was $0.3019 and explains the reverse split would increase the number of authorized but unissued shares, permit the board to issue additional shares without further stockholder action (subject to applicable rules), and provide cash in lieu of fractional shares.

The proxy explains voting mechanics (quorum = holders of at least one-third of voting power), vote thresholds (Amendment requires more FOR than AGAINST, with differing effects if Nasdaq listing conditions are met), tax treatment (generally non-recognition of gain or loss for U.S. Holders except for cash in lieu of fractional shares), and operational effects including adjustments to options/warrants, unchanged par value ($0.0001), and new CUSIP. The board unanimously recommends a vote FOR. The company also discloses it needs substantial additional funding and intends to raise capital via equity (including an At The Market agreement with H.C. Wainwright & Co.) or debt, warning failure to secure funding could materially affect operations.

Schedule 13G/A filed for Intensity Therapeutics, Inc. (INTS) reports that Armistice Capital, LLC and Steven Boyd collectively beneficially own 1,237,113 shares of the issuer's common stock, representing 2.56% of the class. The filing states Armistice Capital is the investment manager of the Master Fund, the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over the reported shares. Mr. Boyd, as managing member, is likewise reported with shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to its Investment Management Agreement.

Intensity Therapeutics amended its bylaws to change the quorum for stockholder meetings from a majority to at least one-third of the voting power, whether present in person, by remote communication, or represented by proxy. The Board adopted the amendment effective August 12, 2025 and filed the full text as Exhibit 3.1. Separately, Nasdaq notified the company that it was not in compliance with the $2,500,000 stockholders' equity requirement, the company raised approximately $6.6 million in July through an at-the-market offering, and its quarterly report for the period ended June 30, 2025 states it believes it meets the equity requirement. Nasdaq has determined the company currently complies but warned that failure to evidence compliance at the next periodic report could lead to delisting procedures.

On 7 Aug 2025, Intensity Therapeutics, Inc. (Nasdaq: INTS) filed a Form 8-K to report the release of its financial results for the three and six months ended 30 Jun 2025. The filing itself does not contain any revenue, EPS or cash-flow figures; instead, management refers investors to the detailed data contained in the accompanying press release (Exhibit 99.1). No other material corporate actions, transactions, or leadership changes were disclosed. Standard forward-looking-statement language and exhibit listings (including an Inline XBRL cover page) are provided, and the company continues to qualify as an emerging growth company.

Intensity Therapeutics (INTS) filed its Q2-25 10-Q showing sharply lower spending but continued losses. R&D expense fell 57% YoY to $1.5 M and G&A fell 23% to $1.2 M, trimming the quarterly net loss to $2.5 M (-$0.13/sh) from $5.0 M (-$0.36/sh) a year ago. For the six-month period, the net loss was $5.9 M (-$0.35/sh) versus $9.6 M in 1H-24.

Liquidity. Cash & equivalents were $2.2 M on 30 Jun 25, down $0.4 M from year-end. Subsequent ATM sales added $6.6 M, and combined April and June public offerings plus Q2 ATM activity brought in $4.1 M during the quarter. Management believes cash now extends into 2H-26, yet the filing still cites substantial doubt about going-concern status.

Clinical pipeline. 鈥� Phase 3 INVINCIBLE-3 (sarcoma) enrollment paused in March due to funding; 23 patients accrued, treatment continues. 鈥� Phase 2 INVINCIBLE-4 (TNBC) ongoing with target completion 1H-26 subject to financing. 鈥� Phase 1/2 IT-01 and Phase 2 INVINCIBLE-2 completed.

Capital structure. Share count rose to 26.2 M from 15.1 M at YE-24 through offerings and ESPP issuances; APIC stands at $74.8 M, while the accumulated deficit reached $72.7 M.

Nasdaq compliance. The company believes recent equity raises restored the minimum $2.5 M shareholders鈥� equity requirement but still faces $1.00 bid-price deficiency.